» Articles » PMID: 12390039

Transbilayer Movement of Monohexosylsphingolipids in Endoplasmic Reticulum and Golgi Membranes

Overview
Journal Biochemistry
Specialty Biochemistry
Date 2002 Oct 23
PMID 12390039
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The transbilayer movement of glycosphingolipids has been characterized in Golgi, ER, plasma, and model membranes using spin-labeled and fluorescent analogues of the monohexosylsphingolipids glucosylceramide and galactosylceramide and of the dihexosylsphingolipid lactosylceramide. In large unilamellar lipid vesicles, monohexosylsphingolipids underwent a slow transbilayer diffusion (half-time between 2 and 5 h at 20 degrees C). Similarly, the inward redistribution of these sphingolipids in the plasma membrane of the hepatocyte-like cell line HepG2 and of erythrocytes was slow. However, in rat liver ER and Golgi membranes, we found a rapid transbilayer movement of spin-labeled monohexosylsphingolipids (half-time of approximately 3 min at 20 degrees C), which suggests the existence of a monohexosylsphingolipid flippase. The transbilayer movement of glucosylceramide in the Golgi and the ER displayed a saturable behavior, was inhibited by proteolysis, did not require Mg-ATP, and occurs in both directions. Treatment with DIDS inhibited the flip-flop of glucosylceramide but not that of phosphatidylcholine. These data suggest that the transbilayer movement of monoglucosylceramide in the ER and in the Golgi involves a protein that could be distinct from that previously evidenced for glycerophospholipids in the ER. In vivo, transbilayer diffusion should promote a symmetric distribution of monohexosylsphingolipids which are synthesized in the cytosolic leaflet. This should allow glucosylceramide rapid access to the lumenal leaflet where it is converted to lactosylceramide. No significant transbilayer movement of lactosylceramide occurred in both artificial and natural membranes over 1 h. Thus, lactosylceramide, in turn, is unable to diffuse to the cytosolic leaflet and remains at the lumenal leaflet where it undergoes the subsequent glycosylations.

Citing Articles

Nonvesicular lipid transfer drives myelin growth in the central nervous system.

Wu J, Kislinger G, Duschek J, Durmaz A, Wefers B, Feng R Nat Commun. 2024; 15(1):9756.

PMID: 39528474 PMC: 11554831. DOI: 10.1038/s41467-024-53511-y.


The therapeutic potential of sphingolipids for cardiovascular diseases.

Yaar Bar S, Pintel N, Abd Alghne H, Khattib H, Avni D Front Cardiovasc Med. 2023; 10:1224743.

PMID: 37608809 PMC: 10440740. DOI: 10.3389/fcvm.2023.1224743.


Pathogenic variants of sphingomyelin synthase SMS2 disrupt lipid landscapes in the secretory pathway.

Sokoya T, Parolek J, Foged M, Danylchuk D, Bozan M, Sarkar B Elife. 2022; 11.

PMID: 36102623 PMC: 9531943. DOI: 10.7554/eLife.79278.


A Fluorescence-based Assay for Measuring Phospholipid Scramblase Activity in Giant Unilamellar Vesicles.

Mathiassen P, Pomorski T Bio Protoc. 2022; 12(6):e4366.

PMID: 35434199 PMC: 8983165. DOI: 10.21769/BioProtoc.4366.


Artificial transmembrane signal transduction mediated by dynamic covalent chemistry.

Bravin C, Duindam N, Hunter C Chem Sci. 2021; 12(42):14059-14064.

PMID: 34760189 PMC: 8565364. DOI: 10.1039/d1sc04741h.